Development FDA Approval Hormones Immune Response 
Drug Discovery World
NOVEMBER 16, 2022
Secreted proteins are a proven class of biologics with largely underutilised therapeutic potential, despite the impact of FDA-approved biologics based on secreted proteins such as insulin, human growth hormone, and erythropoietin.
XTalks
MARCH 8, 2024
Risk factors include aging, hormonal changes, low body weight, low calcium intake and use of certain medications. According to the FDA, Jubbonti is approved for the same indications as Prolia, which include individuals at high risk for fracture including postmenopausal women with osteoporosis and men with osteoporosis.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Find Me Cure
OCTOBER 13, 2019
If you follow our blog you know that we at FindMeCure take updating our readership on treatments in development very seriously. CDK4/6 inhibitors are used alongside hormone therapy. There are antibody drugs targetting those cells that are already FDA approved and there are antibody drugs still in trials.
XTalks
SEPTEMBER 17, 2020
While the table lists acceptable surrogate endpoints for trials of more common conditions, such as asthma, type 2 diabetes and various cancer types, the document also provides key information to developers of certain rare disease therapies. Both surrogate endpoints could be used to support traditional approval of a new drug or biologic.
The Pharma Data
DECEMBER 31, 2020
The vaccine teaches the cells to make a piece of the spike protein, which triggers an immune response to help prevent illness if later exposed to the virus. In mid-December, the FDA approved Orgovyx (relugolix), the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for men with advanced prostate cancer.
Drug Discovery World
AUGUST 21, 2023
Diana Spencer investigates therapies in clinical development for triple-negative breast cancer and asks what future treatments might look like. However, because these cancers are not driven by any of the three molecules that can be blocked by targeted hormone receptor drugs, current treatment options are limited.
The Pharma Data
APRIL 4, 2023
Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, can affect more than one body system simultaneously, and can occur at any time after starting treatment or after discontinuation of treatment. Initiate hormone replacement as indicated. Withhold KEYTRUDA depending on severity.
Expert insights. Personalized for you.
52 
Let's personalize your content